Eris Lifesciences completes acquisition of 19% equity stake in Swiss Parenterals

12 Jun 2024 Evaluate

Eris Lifesciences has completed acquisition of 19% equity stake in Swiss Parenterals (Swiss) from the promoters of the company. Earlier, the company had acquired 51% equity stake in Swiss Parenterals. 

The acquisition of Swiss Parenterals will help company to strengthen India footprint through the launch of a domestic Injectables-focused Branded Formulations business. 

Eris Lifesciences develops, manufactures and commercializes branded pharmaceutical products in select therapeutic areas within the chronic and acute categories of the IPM, such as: cardiovascular; anti-diabetics; vitamins; gastroenterology; and anti-infectives.

Eris Lifesciences Share Price

1552.75 -5.65 (-0.36%)
05-Dec-2025 16:59 View Price Chart
Peers
Company Name CMP
Sun Pharma Inds. 1804.95
Dr. Reddys Lab 1275.05
Cipla 1520.55
Zydus Lifesciences 931.45
Lupin 2097.65
View more..
Register Now to get our Free Newsletter & much more!

© 2025 The Alchemists Ark Pvt. Ltd. All rights reserved. MoneyWorks4Me ® is a registered trademark of The Alchemists Ark Pvt. Ltd.

×